Source: International Congress 2018 – The immune response to tuberculosis: development of biomarkers and diagnostic tools
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
V. Yeremeev (Moscow, Russian Federation), V. Evstifeev (Moscow, Russian Federation), G. Shepelkova (Moscow, Russian Federation), A. Ergeshova (Moscow, Russian Federation), M. Bagirov (Moscow, Russian Federation). MicroRNAs in serum of post primary TB patients.. 4725

Member's Comments

No comment yet.

Related content which might interest you: Lung microRNAs as biomarkers of post primary TB variants. Source: International Congress 2019 – Tuberculosis: diagnosis Year: 2019 MicroRNAs in serum of Interstitial lung diseases patients. Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020 Identification of serum microRNAs in patients with Lymphangioleiomyomatosis Source: International Congress 2017 – Rare diseases Year: 2017 The significance of IP-10 level in blood serum for TB diagnosis in patients with late-stage HIV infection Source: International Congress 2019 – Tuberculosis: diagnosis Year: 2019 MicroRNAs as future therapeutic targets in COPD? Source: Eur Respir J, 49 (5) 1700431; 10.1183/13993003.00431-2017 Year: 2017 Evaluation of IP-10 in blood serum for TB diagnosis in patients with late-stage HIV infection Source: International Congress 2019 – Tuberculosis: diagnosis and scores Year: 2019 Skin test reactivity in non HIV pediatric patients exposed to TB active lung disease. Predictor of active disease Source: Eur Respir J 2005; 26: Suppl. 49, 413s Year: 2005 Characterization and identification of novel serum miRNAs in sepsis patients with different outcomes Source: Annual Congress 2013 –Infection, sepsis and outcomes in ICU Year: 2013 Role of progestrin releasing peptide (ProGRP), a serum based biomarker in early diagnosis of SCLC in cohort of high-risk patient presenting with symptoms related to lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Analysis of serum prohepcidin and hepcidin levels in COPD patients by stages and by patient cathegory Source: Annual Congress 2013 –COPD treatment Year: 2013 Risk factors associated with treatment interruption for 2 months among tuberculosis patients in Taipei Source: Annual Congress 2007 - Tuberculosis control Year: 2007 Profile of selected cytokines in serum and in BAL-fluid in patients with cryptogenic organising pneumonia before and after 3 months of calrithromycin treatment Source: Annual Congress 2010 - Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease Year: 2010 Cytokine profiling of specific T cells in patients after BCG-therapy allows distinction between patients with primary infection and prior contact Source: Annual Congress 2013 –Immunological diagnosis of tuberculosis and latent tuberculosis infection Year: 2013 The diagnostic value of serum soluble CD 14 and IL-10 levels in newly diagnosed pulmonary tuberculosis patients and the relationship with disease extensity Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 Potential translation of plasma microRNA signatures in the risk stratification of COVID-19 patients admitted to the ICU Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Characterization of miRNAs circulating in sepsis patients‘ serum Source: Annual Congress 2011 - Issues in paediatric and neonatal intensive care Year: 2011 Alterations of serum inflammatory biomarkers in the healthy and lung cancer patients before and post chemotherapy Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 MicroRNAs in COPD: small molecules with big potential Source: Eur Respir J, 53 (4) 1900515; 10.1183/13993003.00515-2019 Year: 2019 Immune reactive profiling in subjects at risk of latent tuberculosis infection with TST(+)/IGRA(-) results. Source: International Congress 2018 – Tuberculosis transmission and screening strategies Year: 2018